CagriSema is a combination therapy that includes Cagrilintide, an amylin analog, and Semaglutide. Amylin is a hormone co-secreted with insulin that helps regulate glucose levels and suppress appetite. Cagrilintide mimics amylin’s effects, enhancing satiety and reducing food intake. By combining Cagrilintide with Semaglutide, CagriSema, researchers aim to provide a more rapid and comprehensive approach to menopausal fat belly loss by targeting multiple pathways involved in appetite regulation and glucose metabolism.

Our peptides API formulations are FDA registered and not affiliated, endorsed, or intended to replace Eli Lilly, Novo Nordisk, or other companies' FDA-approved brands such as Victoza, Saxenda, Byetta, Ozempic, Rybelsus, Wegovy, Adlyxin, Trulicity, or Mounjaro.

Please do not add this item to the shopping cart, as it is contract-manufactured upon order. Contact us for minimum quantity, bulk pricing, or packaging inquiries. MQTY runs from 140,000 to 1.64MM counts.